Servier partners with QB3@953 to find and cultivate innovative startups

 

Servier is the second largest French pharmaceutical company with over 3,000 researchers focused on novel treatments for cardiovascular disease, oncology, diabetes, CNS, and Rheumatology.

This partnership is a boon for researchers on both sides of the Atlantic, bringing together Servier’s decades of expertise and QB3@953’s innovative thinking and startup community. Servier will receive a “golden ticket,” which allows Servier to award a bench to a startup company. Servier’s Golden Ticket grant will give a promising Bay Area biotech company access to QB3’s millions of dollars of state-of-the-art research equipment, as well as the opportunity to build a research relationship with an international pharma leader.

Published On: January 5th, 2017Categories: MBC Biolabs News
Feel free to share!